Advaxis, Inc. (ADXS) Given “Buy” Rating at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Advaxis, Inc. (NASDAQ:ADXS) in a research report report published on Friday. The firm currently has a $23.00 price objective on the biotechnology company’s stock.

ADXS has been the subject of a number of other research reports. BidaskClub lowered shares of Advaxis from a hold rating to a sell rating in a research note on Monday, July 31st. ValuEngine lowered shares of Advaxis from a sell rating to a strong sell rating in a research note on Tuesday, August 8th. Finally, Cantor Fitzgerald restated an overweight rating and set a $19.00 price target on shares of Advaxis in a research note on Wednesday, May 31st.

Advaxis (ADXS) opened at 4.95 on Friday. The firm’s market cap is $200.29 million. Advaxis has a one year low of $4.77 and a one year high of $12.66. The company’s 50-day moving average is $6.24 and its 200 day moving average is $7.37.

Advaxis (NASDAQ:ADXS) last announced its quarterly earnings results on Monday, September 11th. The biotechnology company reported ($0.80) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.53) by ($0.27). The business had revenue of $3.05 million for the quarter, compared to the consensus estimate of $3.43 million. Advaxis had a negative net margin of 655.66% and a negative return on equity of 93.54%. Equities analysts anticipate that Advaxis will post ($2.26) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “Advaxis, Inc. (ADXS) Given “Buy” Rating at HC Wainwright” was reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this piece on another domain, it was illegally stolen and reposted in violation of United States and international copyright legislation. The original version of this piece can be accessed at https://www.chaffeybreeze.com/2017/09/19/advaxis-inc-adxs-given-buy-rating-at-hc-wainwright.html.

A number of hedge funds have recently made changes to their positions in ADXS. Stevens Capital Management LP bought a new stake in Advaxis during the 1st quarter valued at $105,000. Voya Investment Management LLC increased its stake in Advaxis by 20.3% during the 2nd quarter. Voya Investment Management LLC now owns 17,612 shares of the biotechnology company’s stock valued at $114,000 after purchasing an additional 2,975 shares in the last quarter. Cutler Capital Management LLC bought a new stake in Advaxis during the 2nd quarter valued at $130,000. Northern Capital Management LLC increased its stake in Advaxis by 14.6% during the 2nd quarter. Northern Capital Management LLC now owns 20,775 shares of the biotechnology company’s stock valued at $135,000 after purchasing an additional 2,650 shares in the last quarter. Finally, Stonebridge Capital Management Inc. bought a new stake in Advaxis during the 2nd quarter valued at $146,000. Institutional investors and hedge funds own 48.06% of the company’s stock.

About Advaxis

Advaxis, Inc is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins.

Receive News & Ratings for Advaxis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply